Katsi Vasiliki, Athanasiadi Eleni, Tsioufis Costas, Tousoulis Dimitris
1st Cardiology Department, Athens Medical School, University of Athens, "Hippokration" Hospital, Athens, Greece.
Curr Hypertens Rev. 2018;14(1):15-20. doi: 10.2174/1573402114666180420170816.
Arterial hypertension is a disease that still affects a major part of the population worldwide, and leads to fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. From the CDC statistical analysis, as regarding to United States, 1 of every 3 adults has high blood pressure, and οnly about half (54%) of them have it under control. Furthermore, all that leads to a nation cost about $46 billion each year. Efforts to find new ways to regulate arterial hypertension are therefore imperative. In our days, a lot of references have been made to the use of a new therapeutic combination, that of azilsartan - an innovative ARB, in combination with chlorthalidone. Ιn fact, it is a combination now prescribed in a number of countries. A significant number of trials shows both azilsartan vs popular antihypertensive drugs, as well as chlorthalidone vs chlorothiazide, to present a better antihypertensive effect. This effect is even greater when the two substances are combined. In this article, we will try to present the latest findings concerning the efficacy, safety and clinical utility of this combination, as well as its adverse events, in comparison with other widely used therapeutic options.
动脉高血压是一种仍影响着全球大部分人口的疾病，会导致致命和非致命的心血管事件，主要是中风和心肌梗死。根据美国疾病控制与预防中心（CDC）的统计分析，在美国，每三名成年人中就有一人患有高血压，其中只有约一半（54%）的人血压得到控制。此外，这一切导致美国每年花费约460亿美元。因此，寻找调节动脉高血压新方法的努力势在必行。如今，人们多次提及使用一种新的治疗组合，即阿齐沙坦（一种创新的血管紧张素Ⅱ受体拮抗剂）与氯噻酮的组合。事实上，这是目前在一些国家所开的一种组合药物。大量试验表明，阿齐沙坦与常用降压药相比，以及氯噻酮与氢氯噻嗪相比，都具有更好的降压效果。当这两种药物联合使用时，这种效果会更显著。在本文中，我们将试图介绍有关这种组合药物的疗效、安全性、临床实用性及其不良事件的最新研究结果，并与其他广泛使用的治疗方案进行比较。
